Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06650501

Dabigatran vs. Apixaban, Edoxaban, or Rivaroxaban as Anti-thrombotic Therapy in Patients With S. Aureus Bacteremia (DABI-SNAP)

Dabigatran vs. Apixaban, Edoxaban, or Rivaroxaban as Anti-thrombotic Therapy in Patients With S. Aureus Bacteremia: the DABI-SNAP Nested Randomized Controlled Trial

Sponsor: Emily McDonald

Conditions S. Aureus Bacteremia S. Aureus Bloodstream Infection Staphylococcus Aureus Bacteremia Staphylococcus Aureus Bloodstream Infection Staphylococcus Aureus Endocarditis Staphylococcus Aureus Septicemia

Interventions Apixaban Dabigatran Rivaroxaban edoxaban

Updated 4 times since 2024 Last updated: Jan 29, 2026 Started: Jan 15, 2026 Primary completion: Jan 31, 2030 Completion: Jan 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06650501, this PHASE4 trial focuses on S. Aureus Bacteremia and S. Aureus Bloodstream Infection and remains actively recruiting participants. Sponsored by Emily McDonald, it has been updated 4 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE4
Nov 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE4
Nov 2024 — Nov 2025 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emily McDonald
University of Melbourne

Data source: McGill University Health Centre/Research Institute of the McGill University Health Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada